Overall asthma control: The relationship between current control and future risk

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 3, 2010, Pages

  Bateman, Eric D ^a   Reddel, Helen K ^b   Eriksson, Göran ^c,d   Peterson, Stefan ^c   Östlund, Ollie ^c   Sears, Malcolm R ^e   Jenkins, Christine ^b   Humbert, Marc ^g   Buhl, Roland ^h   Harrison, Tim W ⁱ   Quirce, Santiago ^j   O'Byrne, Paul M ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ASTRAZENECA R AND D   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e MCMASTER UNIVERSITY   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁱ UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

ACQ; Asthma control; exacerbations; GINA

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

EID: 77949265937     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.11.033     Document Type: Article

References (34)

1. NAEPP (National Asthma Education and Prevention Program). Expert Panel report 3: guidelines for the diagnosis and management of asthma. 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed January 11, 2010.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO workshop report. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute. Updated 2008. Available at: http://www.ginasthma.com. Accessed January 11, 2010.
3. Taylor D.R., Bateman E.D., Boulet L.P., Boushey H.A., Busse W.W., Casale T.B., et al. A new perspective on concepts of asthma severity and control. Eur Respir J 32 (2008) 545-554
4. Reddel H.K., Taylor D.R., Bateman E.D., Boulet L.P., Boushey H.A., Busse W.W., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180 (2009) 59-99
5. Bateman E.D., Bousquet J., Busse W.W., Clark T.J., Gul N., Gibbs M., et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 63 (2008) 932-938
6. Peters D., Chen C., Markson L.E., Allen-Ramey F.C., and Vollmer W.M. Using an asthma control questionnaire and administrative data to predict health-care utilization. Chest 129 (2006) 918-924
7. Wakefield M., Ruffin R., Campbell D., Staugas R., Beilby J., and McCaul K. A risk screening questionnaire for adult asthmatics to predict attendance at hospital emergency departments. South Australian Asthma Reference Panel. Chest 112 (1997) 1527-1533
8. Li D., German D., Lulla S., Thomas R.G., and Wilson S.R. Prospective study of hospitalization for asthma: a preliminary risk factor model. Am J Respir Crit Care Med 151 (1995) 647-655
9. Fuhlbrigge A.L., Kitch B.T., Paltiel A.D., Kuntz K.M., Neumann P.J., Dockery D.W., et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 107 (2001) 61-67
10. Kitch B.T., Paltiel A.D., Kuntz K.M., Dockery D.W., Schouten J.P., Weiss S.T., et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 126 (2004) 1875-1882
11. Dorinsky P.M., Edwards L.D., Yancey S.W., and Rickard K.A. Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy. Clin Ther 23 (2001) 701-714
12. Osborne M.L., Pedula K.L., O'Hollaren M., Ettinger K.M., Stibolt T., Buist A.S., et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest 132 (2007) 1151-1161
13. Combescure C., Chanez P., Saint-Pierre P., Daures J.P., Proudhon H., and Godard P. Assessment of variations in control of asthma over time. Eur Respir J 22 (2003) 298-304
14. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
15. Scicchitano R., Aalbers R., Ukena D., Manjra A., Fouquert L., Centanni S., et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 20 (2004) 1403-1418
16. Kuna P., Peters M.J., Manjra A.I., Jorup C., Naya I.P., Martinez-Jimenez N.E., et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 61 (2007) 725-736
17. Bousquet J., Boulet L.P., Peters M.J., Magnussen H., Quiralte J., Martinez-Aguilar N.E., et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 101 (2007) 2437-2446
18. Rabe K.F., Atienza T., Magyar P., Larsson P., Jorup C., and Lalloo U.G. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368 (2006) 744-753
19. Juniper E.F., Bousquet J., Abetz L., and Bateman E.D. Identifying "well-controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. Respir Med 100 (2006) 616-621
20. Juniper E.F., O'Byrne P.M., Guyatt G.H., Ferrie P.J., and King D.R. Development and validation of a questionnaire to measure asthma control. Eur Respir J 14 (1999) 902-907
21. Juniper E.F., Svensson K., Mörk A.C., and Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 99 (2005) 553-558
22. Svensson K., Mork A.C., and Juniper E.F. ACQ-is five out of seven items acceptable in large clinical studies?. Qual Life Res 12 (2003) 771 Abstract 1276
23. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004) 836-844
24. Bateman E.D., Clark T.J., Frith L., Bousquet J., Busse W.W., and Pedersen S.E. Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the goal study. J Asthma 44 (2007) 667-673
25. Reddel H.K., Jenkins C.R., Marks G.B., Ware S.I., Xuan W., Salome C.M., et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 16 (2000) 226-235
26. Vollmer W.M., Markson L.E., O'Connor E., Sanocki L.L., Fitterman L., Berger M., et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 160 (1999) 1647-1652
27. Vollmer W.M., Markson L.E., O'Connor E., Frazier E.A., Berger M., and Buist A.S. Association of asthma control with health care utilization: a prospective evaluation. Am J Respir Crit Care Med 165 (2002) 195-199
28. Rosi E., Ronchi M.C., Grazzini M., Duranti R., and Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 103 (1999) 232-237
29. Lazarus S.C., Boushey H.A., Fahy J.V., Chinchilli V.M., Lemanske Jr. R.F., Sorkness C.A., et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285 (2001) 2583-2593
30. Jenkins C.R., Thien F.C., Wheatley J.R., and Reddel H.K. Traditional and patient-centred outcomes with three classes of asthma medication. Eur Respir J 26 (2005) 36-44
31. Gibson P.G., Powell H., and Ducharme F.M. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol 119 (2007) 344-350
32. Harkins M.S., Fiato K.L., and Iwamoto G.K. Exhaled nitric oxide predicts asthma exacerbation. J Asthma 41 (2004) 471-476
33. Green R.H., Brightling C.E., McKenna S., Hargadon B., Parker D., Bradding P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002) 1715-1721
34. Jayaram L., Pizzichini M.M., Cook R.J., Boulet L.P., Lemiere C., Pizzichini E., et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27 (2006) 483-494